JSJana Skrickova

Jana Skrickova

*This is an algorithmically generated author record based on publicly available information.

Jana Skrickova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuation maintenance therapy with pemetrexed in patients with non-small-cell lung cancer in the Czech Republic

    by Jana SkřIčková, KateřIna Fröhlich, Matyáš Kuhn, Zbyněk Bortlíček, Karel Hejduk, Miloš Pešek, Vítězslav Kolek, Ivona Grygárková, Leona Koubková, Markéta Černovská, et al.

    Karcinom plic zaujímá přední místa jak v incidenci, tak v mortalitě nádorových onemocnění celosvětově i v České republice. V posledních letech zaznamenala léčba NSCLC prudký rozvoj. Již v době stanovení diagnózy je snahou co nejpřesněji určit morfologickou diagnózu a pokud je to indikováno, provést genetické testování. Toto platí především o nedlaždicobuněčných NSCLC. V roce 2013 byla publikovaná účinnost a bezpečnost pokračovací udržovací léčby (continuation maintenace) monoterapií pemetrexedem a díky pozitivnímu výsledku je tato léčba možná od května 2013 v České republice. V naší práci prezentujeme soubor 134 hodnocených pacientů, kteří absolvovali výše uvedenou léčbu. V reálné klinické praxi v České republice bylo dosaženo léčbou pemetrexedem v pokračovací udržovací léčbě lepších výsledků než v registrační studii a léčba byla velmi dobře snášena

  • Open Access

    The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

    by Bohdan Kadlec, Jana Skrickova, Zdenek Merta, Ladislav Dusek, Jiri Jarkovsky

    Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. In a large cohort of lung cancer patients we monitored the incidence of venous thromboembolism and we identified groups of patients with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favourably affect their morbidity and mortality.


  • The Limits of Surgical Treatment of Non‐Small Cell Lung Cancer

    by Jana Skřičková, S. Špelda, Jana Kaplanova

    Summary: Between January 1, 1991 until December 31, 1996, 286 patients with non‐small cell lung cancer were diagnosed and treated in the Department of Tuberculosis and Respiratory Diseases and Palliative Care Unit in Babice nad Svitavou, Czech Republic. There were 251 (87.8 %) males and 35 (12.2 %) females. The mean age of the whole group was 63.8 years. According to TNM staging (regarding the locoregional extension of the disease) as the only criterion 112 patients (39.2 %) were eligible for surgical resection of primary lung tumour. However lung surgery was performed in 57 patients (19.9 %) with successful radical resection in 49 cases (17.1 %) out of 286. Surgical procedure was contraindicated in 55 (49.1 %) out of 112 potentially resectable patients mostly because of limited cardiopulmonary function. The strategy of neoadjuvant treatment before the resection of lung tumour was used for 12 (4.2 %) patients. Chemotherapy, radiotherapy or the combination of both treatment modalities was used in 121 (42.3 %) patients. Symptomatic therapy alone was chosen in 104 (36.4 %) cases. The performance of radical resection of lung tumours resulted in a significant influence on the overall survival in the subgroup of all patients with potentially locoregionally operable disease according to the TNM staging. The median survival period reached 17 months if radical resection was done compared to 8.5 months if radical resection was not performed. This difference is statistically significant, p = 0.05.